AegirBio is a Swedish diagnostics company that was founded to offer tests to monitor and optimize the dosage of biological drugs via its’ unique patented technology platform. Biological drugs are the segment within the pharmaceutical industry where use is growing the fastest.
Meanwhile, drug levels vary enormously (up to 100-fold) in patients receiving standard doses of biological drugs. "One size fits all" results in patients with low drug levels not responding to treatment, while excessive drug levels increase the risk of serious side effects. In approximately 55 percent of cases, this uncertainty in dosing leads to over- or underdosing, which results in unnecessary costs, inadequate results and a higher proportion of patients with severe side effects.
Through completed acquisitions, the Company has secured long-term access to key technologies and opened up new areas of application. With these acquisitions, AegirBio, starting in laboratory tests, has in a short time added technologies and competence to the Company to take the step towards the multi-diagnostic company that is the goal.
AegirBio is now building its business around technologies for:
The acquisitions give the Company the tools to develop new diagnostics to make it possible and easy for people to monitor their health problems themselves, where the Company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and provide accurate and simple transferable results.